Adherence to and persistence with non-Vitamin K-antagonist oral anticoagulants: Does the number of pills per day matter?

Current Medical Research and Opinion

Volumn 31, Issue 10, 2015, Pages 1845-1847

  Rubboli, Andrea ^a  

^a MAGGIORE HOSPITAL   (Italy)

Author keywords

Adherence; NOACs; Non vitamin K antagonist oral anticoagulants; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH BEHAVIOR; HUMAN; LONG TERM CARE; MEDICATION COMPLIANCE; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOCIAL ASPECT; SOCIOECONOMICS; UNITED STATES; FEMALE; MALE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; HUMANS; MALE; RIVAROXABAN;

EID: 84942255954     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1086993     Document Type: Review

References (14)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
2. Suryanaryan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth? Semin Thromb 2014;40:852-9
3. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am J Cardiol 2008;155:772-9
4. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-50
5. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcome: a systematic review. Br J Clin Pharmacol 2014;78:684-98
6. Nieuwlaat R, Connolly BJ, Hubers LM, et al. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res 2012;129:715-19
7. Jansa M, Hernandez C, Vidal M, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns 2010;81:161-8
8. Schulman S. Advantages and limitations of new oral anticoagulants. J Intern Med 2014;275:1-11
9. Nelson WW, Song X, Thomson E, et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opinion 2015. [Epub ahead of print]. doi: 10. 1185/03007995. 2015. 1074064
10. Laliberte F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90
11. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
13. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-9
14. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92